Pathogenetic rationale for the use of cobalt-containing drugs in the treatment of anemia
- Authors: Khafizyanova R.K., Zalyalyutdinova L.N., Bakirova N.E., Murzagaleeva G.N.
- Issue: Vol 81, No 6 (2000)
- Pages: 507-511
- Section: Reviews
- URL: https://bakhtiniada.ru/kazanmedj/article/view/96181
- DOI: https://doi.org/10.17816/kazmj96181
- ID: 96181
Cite item
Full Text
Abstract
Anemia is a clinical and hematological syndrome, which is understood as a decrease in the number of erythrocytes and / or hemoglobin. It accompanies many pathological processes and worsens the quality of life of patients. Anemia affects about 20% of men, 35% of women and 40% of children in the world [37]. Due to the imbalance in the erythron system, anemias are divided into three main groups: dyserythropoietic (erythropoiesis disturbance), hemolytic (increased destruction of erythrocytes) and hemorrhagic [18]. A separate group is made up of iron, B12-, folic- and protein-deficient anemias that occur when there is a lack of “building material” for the formation of erythrocytes
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
R. Kh. Khafizyanova
Author for correspondence.
Email: info@eco-vector.com
Russian Federation
L. N. Zalyalyutdinova
Email: info@eco-vector.com
Russian Federation
N. E. Bakirova
Email: info@eco-vector.com
Russian Federation
G. N. Murzagaleeva
Email: info@eco-vector.com
Russian Federation
References
Supplementary files
